How many clinical trials are tracked for nervous system diseases?

20 trials are tracked, 5 with published results.

nervous system diseases Research

Nervous system diseases: what the trials found

New evidence indicates that Ataluren showed a statistically significant reduction in 6-Minute Walk Distance (6MWD) at week 72 when analyzed using an Intent-to-Treat (ITT) population ¹. However, this same metric did not reach statistical significance in the Modified Intention-to-Treat (mITT) population ¹. In a separate study of Ataluren, no significant change was observed in 6MWD at week 48 ².

Regarding agitation management, Brexpiprazole combined with OPC-34712 demonstrated a statistically significant reduction in the Cohen-Mansfield Agitation Inventory (CMAI) total score after 12 weeks of treatment ⁵, though it did not significantly impact Clinical Global Impression-Severity of Illness (CGI-S) scores related to agitation ⁵. A different trial using the same combination did not reach statistical significance for CMAI scores ³.

In the management of seizures, SHP615 demonstrated a response rate of 80% in a small cohort ⁸. In this study, patients showed sustained absence of seizure activity for at least 1, 4, and 6 hours at rates of 68.0%, 36.0%, and 32.0%, respectively ⁸. A smaller trial reported that no participants required additional anticonvulsant medication for ongoing status epilepticus after administration of SHP615 ⁷.

For fibromyalgia, TNX-102 SL (2.8mg) showed a reduction in both the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score and Function Domain Score at week 12 ⁶.

For the clinician treating this condition

Ataluren shows mixed evidence regarding its impact on 6MWD, with significance only observed in ITT analysis ¹.
Brexpiprazole combined with OPC-34712 significantly reduces Cohen-Mansfield Agitation Inventory (CMAI) scores in some instances but not all [3, 5].
SHP615 demonstrated a high response rate and sustained absence of seizure activity in patients with status epilepticus ⁸.
TNX-102 SL (2.8mg) is associated with improvements in both symptom and function domains for fibromyalgia ⁶.

AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.